Title : The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer.

Pub. Date : 2014 Mar-Apr

PMID : 24492292






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer. saracatinib SRC proto-oncogene, non-receptor tyrosine kinase Homo sapiens
2 Here, we investigated the antitumor activity of the combination of trastuzumab and the SRC inhibitor saracatinib in ErbB2-overexpressing trastuzumab-resistant gastric cancer. saracatinib SRC proto-oncogene, non-receptor tyrosine kinase Homo sapiens